Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hammond, E. J.
Right arrow Articles by Wilder, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hammond, E. J.
Right arrow Articles by Wilder, B. J.
NEUROLOGY 1987;37:346
© 1987 American Academy of Neurology

Cholinergic modulation of human P3 event-related potentials

Edward J. Hammond, PhD, Kimford J. Meador, MD, Ronald Aung-Din, MD and B. J. Wilder, MD

Neurology Service, Veterans Administration Medical Center, and the Department of Neurology, University of Florida, Gainesville, FL.

A paradigm for studying relations between behavioral, neurochemical, and electrophysiologic processes is presented. Scopolamine, a centrally acting anticholinergic agent, abolished the human auditory P3 event-related potential, but had no measurable effect on the pattern reversal visual evoked potential or alpha rhythm. Recent memory was significantly impaired, but assessment of digit span, reaction time, and distant memory showed no impairment. Physostigmine, an anticholinesterase, restored the P3 and reversed the recent memory impairment. These results strongly suggest a cholinergic role in generation of P3 potential and support the concept that P3 generation is related to memory processes.

Address correspondence and reprint requests to Dr. Hammond, Neurology Service (127), Veterans Administration Medical Center, Gainesville, FL 32602.

Received December 29, 1985. Accepted for publication June 6, 1986.




This article has been cited by other articles:


Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
E. R. Marcantonio, J. L. Rudolph, D. Culley, G. Crosby, D. Alsop, and S. K. Inouye
Review Article: Serum Biomarkers for Delirium
J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2006; 61(12): 1281 - 1286.
[Abstract] [Full Text] [PDF]

Home page
 Learn. Mem.Home page
M. Mesulam
The Cholinergic Lesion of Alzheimer's Disease: Pivotal Factor or Side Show?
Learn. Mem., January 1, 2004; 11(1): 43 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Behav Cogn Neurosci RevHome page
P. M. Greenwood and R. Parasuraman
Normal Genetic Variation, Cognition, and Aging
Behav Cogn Neurosci Rev, December 1, 2003; 2(4): 278 - 306.
[Abstract] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
M. A. Kuskowski, G. Morley, S. M. Malone, M. W. Dysken, and A. Okaya
Hydergine Treatment and Psychophysiological Measures in Primary Degenerative Dementia
J Geriatr Psychiatry Neurol, January 1, 1990; 3(1): 41 - 47.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by AAN Enterprises, Inc.